High-dose melphalan followed by autologous stem cell transplant (ASCT) has been a cornerstone of therapy for multiple myeloma (MM) since landmark articles demonstrating clinical benefit were published over 10 years ago. 1 As adequate stem cell collection is a prerequisite for successful ASCT, it was quickly appreciated that prior use of the alkylating agent melphalan resulted in an inability to collect stem cells in approximately 60% of patients who had received more than five cycles of therapy. 2 As a consequence of this observation, the use of lower dose melphalan was abandoned as an induction therapy in patients in whom stem cell transplant was later being considered and was replaced with dexamethasone-based induction regimens. Following the use of dexamethasone alone or in combination with adriamycin and vincristine-based (VAD) chemotherapy, stem cell collection is successful in the vast majority of patients. 3 However, recent positive clinical trial results have prompted a shift in the choice of induction therapy to regimens combining an immunomodulatory drug such as thalidomide, or more recently, lenalidomide with dexamethasone in preference to VAD chemotherapy. 4, 5 Thalidomide is not generally myelosuppressive and in large studies, stem cell collection numbers were only modestly lower than that seen with VAD chemotherapy, with 84% of patients collecting sufficient stem cells for tandem transplant. 6 Promising results on the use of lenalidomide and dexamethasone have resulted in a recommendation for the use of this combination in newly diagnosed patients heading for transplant. 7 However, one recent analysis of stem cell collection following lenalidomide induction indicated that stem cell collection yields are compromised in some patients. 8 We read with interest the paper by Mazumder et al. on the effect of lenalidomide on stem cell mobilization. 9 We report here further evidence for a detrimental effect of lenalidomide on the ability to mobilize stem cells successfully. Specifically, in 9 of 20 (45%) patients who received lenalidomide at our center as induction therapy, a successful stem cell collection (42 Â 10 6 CD34-positive cells kg À1 ) following granulocyte colony-stimulating factor (G-CSF) 10 mg kg À1 alone could not be obtained or was severely comprised at first collection attempt by prior lenalidomide use.
We performed a retrospective chart review after the clinical observation of difficulty in mobilizing stem cells in patients treated with lenalidomide and dexamethasone was made. MM patients undergoing stem cell collection between January 2005 and October 2007 were analyzed for type and duration of induction therapy, collection efficacy and engraftment in patients who went to transplant. All data were extracted from patient medical records and from our transplant database. The study was approved by the Mayo Foundation Institutional Review Board.
Sixty-one patients were identified who underwent stem cell mobilization using G-CSF at 10 mg kg
À1
, with collection beginning on day 5. Of the 61 patients, 20 underwent induction therapy with lenalidomide and dexamethasone and the remaining 41 patients received other induction therapies such as thalidomide and dexamethasone, VAD-or bortezomibcontaining regimens. Baseline characteristics between the two groups were statistically identical for gender, age, hemoglobin, platelets, creatinine, calcium, b-2-microglobulin, C-reactive protein, isotype, monoclonal protein level and presence of lytic bone disease and bone marrow plasma cell percentage (not shown). Baseline mean total leukocyte count was slightly lower in the lenalidomide-treated group (mean 5.1 versus 6.1; P ¼ 0.032 for Wilcoxon rank sum test). All the patients underwent collection with processing of five total blood volumes, using a mixture of heparin citrate (6000 U heparin l À1 acid citrate dextrose solution A (ACDA)). Patient details and therapy leading up to time of transplantation are noted under Supplementary data. The selected criteria for failure of first and total stem cell collection were defined as:
Collection not attempted as peripheral blood CD34
þ cell count consistently o10 cells ml In 41 patients who received thalidomide and dexamethasone, VAD chemotherapy or a bortezomib-based regimen as induction, only three patients (7.3%) failed to achieve successful first collection using the criteria above. However, in the 20 patients who initially received therapy with lenalidomide, stem cell collection was unsuccessful at the first attempt in 9 patients (45%), a statistically significant difference (P ¼ 0.0011 for Fisher's exact test). Furthermore, stem cell numbers collected were severely compromised even in those patients who had sufficient cells to proceed to transplant, with 13 of 20 (65%) failing to collect our target of at least 5 Â 10 6 CD34 þ cells per kg body weight ( Table 1) . The mean peripheral blood CD34 þ cell count (14.0 versus 28.9 cells ml À1 ; P ¼ 0.0002 for Wilcoxon rank sum test) and mean total CD34 þ cells collected (5.1 Â 10 6 versus 7.4 Â 10 6 cells kg À1 ; P ¼ 0.0025 for Wilcoxon rank sum test) were significantly lower in the patients who received lenalidomide versus other induction therapies. The mean number of days of collection (3.6 versus 2.8 days; P ¼ 0.07 for Wilcoxon rank sum test) was greater in the patients who received lenalidomide, although this was not statistically significant ( Figure 1 ).
The likelihood of having a successful stem cell collection decreased with increasing duration/number of cycles of lenalidomide treatment (Table 1 ). This observation suggests that stem cell collection earlier during the course of induction with lenalidomide may be necessary.
Re-collection in the majority of lenalidomide-treated patients when combined with the first collection provided cells sufficient for at least one transplant. Indeed, of the nine patients who failed first collection in the lenalidomide-treated group, five were remobilized successfully with granulocyte macrophage colony-stimulating factor (GM-CSF) in addition to G-CSF or with G-CSF at 20 mg kg À1 , three patients have not yet had another attempt at remobilization and one patient proceeded with stem cell transplant at an outside facility and had difficulty with platelet engraftment (1.8 Â 10 6 CD34 þ cells kg À1 infused) requiring platelet transfusions even after day þ 100. Of the three patients in the non-lenalidomide group who failed first collection, two were remobilized successfully with the addition of GM-CSF and one patient failed second collection. Thus, when two collection attempts are allowed and only a single transplant is contemplated, 40 of 41 (97%) patients treated without lenalidomide and 16 of 17 (94%) lenalidomide-treated patients may ultimately undergo transplant.
These findings have implications for the management of patients with MM proceeding to ASCT. Given the relative inefficiency of stem cell mobilization after lenalidomide-based induction therapy, other strategies for mobilization of stem cells following lenalidomide induction such as cyclophosphamide or AMD 3100 along with G-CSF may be considered. A lenalidomide 'holiday' may be advisable prior to stem cell collection, and limiting the number of monthly cycles of lenalidomide prior to mobilization may initially be optimal. Arizona, Scottsdale, AZ, USA E-mail: paripati.harshita@mayo.edu Table 1 Results of stem cell collection Letters to the Editor
